MCPC — MENOPAUSE CARE PROFESSIONAL
CERTIFICATE LATEST UPDATED 2026-2027 ACTUAL
FINAL PRACTICE EXAM WITH ALL POSSIBLE MOST
TESTED 100 PRACTICE QUESTIONS AND 100%
CORRECT VERIFIED ANSWERS WITH DETAILED
RATIONALES PLUS CERTIFIED ANSWER KEY
RATED A+ MOST RECENT!!!
A 51-year-old woman reports 14 months of
amenorrhea, new-onset vasomotor symptoms, and
vaginal dryness. Which laboratory value would be
most consistent with a diagnosis of menopause?
A) FSH 8 mIU/mL, Estradiol 45 pg/mL
B) FSH 12 mIU/mL, Estradiol 50 pg/mL
C) FSH 75 mIU/mL, Estradiol 15 pg/mL
D) FSH 5 mIU/mL, Estradiol 80 pg/mL
C
Rationale: Menopause is characterized by ovarian
,follicular depletion, leading to markedly elevated
follicle-stimulating hormone (FSH) levels (typically
>30-40 mIU/mL) and very low estradiol levels. This
reflects the loss of negative feedback on the
pituitary.
1. According to the most recent guidelines, what is
the primary indication for systemic menopausal
hormone therapy (MHT)?
A) Prevention of cardiovascular disease in all
postmenopausal women
B) Management of moderate to severe
vasomotor symptoms
C) Prevention of cognitive decline
D) Treatment of stress urinary incontinence
B
Rationale: The primary and most evidence-
based indication for systemic MHT is the relief
of moderate-to-severe vasomotor symptoms
(hot flashes and night sweats) that negatively
impact quality of life. It is not approved for
primary prevention of chronic diseases.
,2. A 55-year-old woman with an intact uterus is
prescribed systemic estrogen therapy for severe
hot flashes. Which progestogen is absolutely
required to be added to her regimen?
A) Conjugated equine estrogens
B) Micronized progesterone
C) Medroxyprogesterone acetate
D) Bazedoxifene
B
Rationale: In a woman with an intact uterus,
unopposed estrogen significantly increases the
risk of endometrial hyperplasia and cancer.
The addition of a progestogen, such as
micronized progesterone or
medroxyprogesterone acetate, is required for
endometrial protection. Bazedoxifene is a
SERM, not a progestogen.
3. A patient asks about the "window of
opportunity" hypothesis for MHT. What is the
most accurate statement regarding this
concept?
A) MHT is only effective for symptom relief if
, started after age 65.
B) The benefits of MHT are maximized and risks
minimized when initiated in women under 60 or
within 10 years of menopause.
C) The window refers to the 5-year period after
menopause when MHT can cure osteoporosis.
D) There is no scientific basis for the timing of
MHT initiation.
B
Rationale: The timing hypothesis suggests that
the balance of benefits and risks of MHT is
more favorable in younger, recently
menopausal women (typically <60 years old or
within 10 years of menopause) compared to
older women, particularly regarding
cardiovascular outcomes.
4. A 53-year-old woman who underwent a
hysterectomy with bilateral salpingo-
oophorectomy 2 years ago presents with severe
hot flashes. What is the most appropriate
hormonal therapy?
A) Combined estrogen-progestogen therapy
CERTIFICATE LATEST UPDATED 2026-2027 ACTUAL
FINAL PRACTICE EXAM WITH ALL POSSIBLE MOST
TESTED 100 PRACTICE QUESTIONS AND 100%
CORRECT VERIFIED ANSWERS WITH DETAILED
RATIONALES PLUS CERTIFIED ANSWER KEY
RATED A+ MOST RECENT!!!
A 51-year-old woman reports 14 months of
amenorrhea, new-onset vasomotor symptoms, and
vaginal dryness. Which laboratory value would be
most consistent with a diagnosis of menopause?
A) FSH 8 mIU/mL, Estradiol 45 pg/mL
B) FSH 12 mIU/mL, Estradiol 50 pg/mL
C) FSH 75 mIU/mL, Estradiol 15 pg/mL
D) FSH 5 mIU/mL, Estradiol 80 pg/mL
C
Rationale: Menopause is characterized by ovarian
,follicular depletion, leading to markedly elevated
follicle-stimulating hormone (FSH) levels (typically
>30-40 mIU/mL) and very low estradiol levels. This
reflects the loss of negative feedback on the
pituitary.
1. According to the most recent guidelines, what is
the primary indication for systemic menopausal
hormone therapy (MHT)?
A) Prevention of cardiovascular disease in all
postmenopausal women
B) Management of moderate to severe
vasomotor symptoms
C) Prevention of cognitive decline
D) Treatment of stress urinary incontinence
B
Rationale: The primary and most evidence-
based indication for systemic MHT is the relief
of moderate-to-severe vasomotor symptoms
(hot flashes and night sweats) that negatively
impact quality of life. It is not approved for
primary prevention of chronic diseases.
,2. A 55-year-old woman with an intact uterus is
prescribed systemic estrogen therapy for severe
hot flashes. Which progestogen is absolutely
required to be added to her regimen?
A) Conjugated equine estrogens
B) Micronized progesterone
C) Medroxyprogesterone acetate
D) Bazedoxifene
B
Rationale: In a woman with an intact uterus,
unopposed estrogen significantly increases the
risk of endometrial hyperplasia and cancer.
The addition of a progestogen, such as
micronized progesterone or
medroxyprogesterone acetate, is required for
endometrial protection. Bazedoxifene is a
SERM, not a progestogen.
3. A patient asks about the "window of
opportunity" hypothesis for MHT. What is the
most accurate statement regarding this
concept?
A) MHT is only effective for symptom relief if
, started after age 65.
B) The benefits of MHT are maximized and risks
minimized when initiated in women under 60 or
within 10 years of menopause.
C) The window refers to the 5-year period after
menopause when MHT can cure osteoporosis.
D) There is no scientific basis for the timing of
MHT initiation.
B
Rationale: The timing hypothesis suggests that
the balance of benefits and risks of MHT is
more favorable in younger, recently
menopausal women (typically <60 years old or
within 10 years of menopause) compared to
older women, particularly regarding
cardiovascular outcomes.
4. A 53-year-old woman who underwent a
hysterectomy with bilateral salpingo-
oophorectomy 2 years ago presents with severe
hot flashes. What is the most appropriate
hormonal therapy?
A) Combined estrogen-progestogen therapy
